Timing was a decisive factor in the Federal Trade Commission's suit against Shire PLC subsidiary Shire ViroPharama Inc. over its filing of 24 citizen petitions, as a court found that the agency had not shown Shire was "about to violate" a law and dismissed the complaint.
The agency filed suit against Shire in February 2017 alleging the company's use of FDA's citizen petition process constituted unfair...






